Rapid assessment of CAR T-cell therapy strategies for multiple myeloma with the cell avidity analysis
In this application note, we highlight cell avidity and in vivo experiments performed in collaboration with the team of Dr. Eric Smith (DanaFarber Cancer Institute) and Prof. Carlos de Larrea (Hospital Clínic Barcelona) and show how one can use the z-Movi Cell Avidity Analyzer to:
1. Rapidly identify new, effective CAR T-cell therapy candidates for multiple myeloma through cell avidity measurements.
2. Predict in vivo outcomes by comparing cell avidity outcomes between CAR T-cell populations.
3. Retrieve data from different CAR T-cell populations within 24 hours.
